Skip to main content
. Author manuscript; available in PMC: 2015 May 20.
Published in final edited form as: Blood Lymphat Cancer. 2014 Jun 3;2014(4):15–27. doi: 10.2147/BLCTT.S49780

Figure 2.

Figure 2

Mechanisms of action of elotuzumab. The primary mechanism of action of elotuzumab against myeloma cells is NK cell-mediated ADCC. Elotuzumab can also interfere with the adhesion of myeloma cells to BMSC, or can induce NK cell activation directly through binding CS1 expressed on NK cells.

Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; BMSC, bone marrow stromal cells; NK, natural killer.